FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * COLUMN GROUP II, LP 2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900
3. Date of Earliest Transaction (MM/DD/YYYY)
9/1/2021
(Street)
SAN FRANCISCO, CA 94129
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/1/2021    S    6904  D $35.0163 (1) 27521  I  See Footnote (2)
Common Stock  9/1/2021    S    8976  D $35.3915 (3) 18545  I  See Footnote (2)
Common Stock  9/1/2021    S    8805  D $35.0575 (4) 25620  I  See Footnote (5)
Common Stock  9/1/2021    S    7064  D $35.4592 (6) 18556  I  See Footnote (5)
Common Stock  9/2/2021    S    18545  D $35.4318 (7) 0  I  See Footnote (2)
Common Stock  9/2/2021    S    18556  D $35.4316 (8) 0  I  See Footnote (5)
Common Stock                 2568674  D (9)  
Common Stock                 91  I  See Footnote (10)
Common Stock                 1599417  I  See Footnote (11)
Common Stock                 145401  I  See Footnote (12)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $34.21 to $35.20, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
(2)  These securities are directly held by Peter Svennilson.
(3)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.21 to $35.87, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
(4)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $34.23 to $35.22, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
(5)  These securities are directly held by David Goeddel.
(6)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $35.23 to $35.87, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
(7)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $34.91 to $35.85, inclusive. Peter Svennilson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
(8)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $34.94 to $35.85, inclusive. David Goeddel undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
(9)  The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
(10)  The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the TCG II GP Managing Partners and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
(11)  The securities are directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
(12)  The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
COLUMN GROUP II, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Column Group II GP, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

PONOI CAPITAL, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Ponoi Management, LLC
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Ponoi Capital II, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Ponoi II Management, LLC
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Kutzkey Tim
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

GOEDDEL DAVID V
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Svennilson Peter
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X

Column Group LLC
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129

X


Signatures
/s/ James Evangelista, as Attorney-in-fact for David Goeddel 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Peter Svennilson 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Tim Kutzkey 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Ponoi Capital II LP 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Ponoi II Management LLC 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Ponoi Capital LP 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for Ponoi Management LLC 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for The Column Group II LP 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for The Column Group II GP LP 9/3/2021
**Signature of Reporting Person Date
/s/ James Evangelista, as Attorney-in-fact for The Column Group LLC 9/3/2021
**Signature of Reporting Person Date
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more RAPT Therapeutics Charts.
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more RAPT Therapeutics Charts.